- Home
- DPG vs VERV Comparison
DPG vs VERV Comparison
Compare DPG & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPG
- VERV
- Stock Information
- Founded
- DPG 2011
- VERV 2018
- Country
- DPG United States
- VERV United States
- Employees
- DPG N/A
- VERV N/A
- Industry
- DPG Trusts Except Educational Religious and Charitable
- VERV Medicinal Chemicals and Botanical Products
- Sector
- DPG Finance
- VERV Health Care
- Exchange
- DPG Nasdaq
- VERV Nasdaq
- Market Cap
- DPG 451.3M
- VERV 475.0M
- IPO Year
- DPG N/A
- VERV 2021
- Fundamental
- Price
- DPG $12.00
- VERV $7.28
- Analyst Decision
- DPG
- VERV Strong Buy
- Analyst Count
- DPG 0
- VERV 4
- Target Price
- DPG N/A
- VERV $25.75
- AVG Volume (30 Days)
- DPG 150.1K
- VERV 1.3M
- Earning Date
- DPG 01-01-0001
- VERV 02-28-2025
- Dividend Yield
- DPG 9.09%
- VERV N/A
- EPS Growth
- DPG N/A
- VERV N/A
- EPS
- DPG N/A
- VERV N/A
- Revenue
- DPG N/A
- VERV $24,396,000.00
- Revenue This Year
- DPG N/A
- VERV $106.46
- Revenue Next Year
- DPG N/A
- VERV N/A
- P/E Ratio
- DPG N/A
- VERV N/A
- Revenue Growth
- DPG N/A
- VERV 219.91
- 52 Week Low
- DPG $7.90
- VERV $4.31
- 52 Week High
- DPG $13.58
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- DPG 59.47
- VERV 47.08
- Support Level
- DPG $11.86
- VERV $7.44
- Resistance Level
- DPG $12.02
- VERV $9.31
- Average True Range (ATR)
- DPG 0.13
- VERV 0.67
- MACD
- DPG 0.02
- VERV -0.12
- Stochastic Oscillator
- DPG 89.76
- VERV 14.01
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting primarily from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.